- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
The Day Reports on 'New Mission' of Company's Groton Site
The Day (of New London) featured a front page story about the evolving role of Worldwide Research & Development's Groton site, which is being transformed into the company's drug-development hub: the Center for Discovery and Development Sciences.
"Groton is set up to bring in development work and progress it," said Jim Spavins, Head of PharmaTherapeutics Pharmaceutical Sciences and one of the colleagues interviewed in the article. "Groton is a great place to get a team of experts together to run these programs."
The article highlighted Groton's role in helping the company gain FDA approval for cancer drug Xalkori, which defied the typical eight-to-10-year industry average for bringing new drugs to market by taking Xalkori from discovery to bedside in just four years.
The Connecticut site's drug development expertise helped accelerate Xalkori's path to approval by determining the best formulation and then quickly developing the quantities needed to conduct clinical studies.
"Groton took a process that usually takes nine to 12 months ... and compressed it to three months," Spavins said. "Because of the stories coming in from the clinics, there was an urgency to deliver as quickly as possible."
Click here to read the full article.
Stock Symbol: PFE Stock Exchange: NYSE
Stock Quote at: Jun 19 2013 4:01PM
|Last 29.10||Change -0.30|
|Day High||29.81||52 Wk. High||31.15|
|Day Low||28.90||52 Wk. Low||22.00|
Our press kit provides information that might help you write stories or simply find out more about Pfizer.